Journal
MOLECULAR MEDICINE REPORTS
Volume 24, Issue 5, Pages -Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/mmr.2021.12422
Keywords
liver cancer; tumor protein translationally controlled 1 antisense RNA 1; prognosis; proliferation; migration; invasion
Categories
Ask authors/readers for more resources
TPT1-AS1, a long non-coding RNA, is upregulated in liver cancer tissues and cell lines, and its overexpression is associated with poor prognosis, TNM stage lymph node metastasis. Knockdown of TPT1-AS1 inhibits cell proliferation, migration, and invasion, suggesting its potential as a therapeutic target for liver cancer.
Long non-coding RNA (lncRNA) tumor protein translationally controlled 1 antisense RNA 1 (TPT1-AS1) serves as an oncogene in several tumors, including ovarian and cervical cancer. However, the functional role of TPT1-AS1 in liver cancer (LC) is not completely understood. The present study aimed to explore the role of TPT1-AS1 in LC. In this study, the reverse transcription-quantitative PCR results demonstrated that TPT1-AS1 expression was significantly upregulated in LC tissues and cell lines compared with adjacent paracancerous tissues and THLE-3 cells, respectively. Elevated TPT1-AS1 expression was significantly associated with TNM stage lymph node metastasis and poor prognosis in patients with LC, as determined via chi(2) and Kaplan-Meier survival analyses. By constructing TPT1-AS1 knockdown LC cell lines (HepG2 and SNU-182), loss-of-function experiments, including Cell Counting Kit-8, colony formation, flow cytometry, wound healing and Transwell assays, were performed to explore the function role of TPT1-AS1 in LC in vitro. The results demonstrated that TPT1-AS1 knockdown inhibited LC cell proliferation, G(1)/S transition, migration and invasion compared with the small interfering RNA (si)-negative control (NC) group. Mechanistically, TPT1-AS1 knockdown markedly decreased CDK4, N-cadherin and Vimentin expression levels, but notably increased p21 and E-cadherin expression levels compared with the si-NC group. Therefore, the results of the present study suggested that TPT1-AS1 might serve as a promising therapeutic target for LC treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available